nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—Iritis—Nelfinavir—acquired immunodeficiency syndrome	0.0578	0.0666	CcSEcCtD
Tafluprost—Iritis—Efavirenz—acquired immunodeficiency syndrome	0.044	0.0507	CcSEcCtD
Tafluprost—Uveitis—Ritonavir—acquired immunodeficiency syndrome	0.0423	0.0488	CcSEcCtD
Tafluprost—Iritis—Ritonavir—acquired immunodeficiency syndrome	0.0389	0.0449	CcSEcCtD
Tafluprost—Dry eye—Didanosine—acquired immunodeficiency syndrome	0.0233	0.0269	CcSEcCtD
Tafluprost—Photophobia—Zidovudine—acquired immunodeficiency syndrome	0.0179	0.0206	CcSEcCtD
Tafluprost—Eye irritation—Saquinavir—acquired immunodeficiency syndrome	0.0167	0.0192	CcSEcCtD
Tafluprost—Photophobia—Delavirdine—acquired immunodeficiency syndrome	0.015	0.0173	CcSEcCtD
Tafluprost—Dry eye—Delavirdine—acquired immunodeficiency syndrome	0.0148	0.017	CcSEcCtD
Tafluprost—Eye pain—Indinavir—acquired immunodeficiency syndrome	0.0142	0.0164	CcSEcCtD
Tafluprost—Photophobia—Ritonavir—acquired immunodeficiency syndrome	0.0139	0.016	CcSEcCtD
Tafluprost—Dry eye—Saquinavir—acquired immunodeficiency syndrome	0.0132	0.0152	CcSEcCtD
Tafluprost—Photophobia—Lamivudine—acquired immunodeficiency syndrome	0.0128	0.0147	CcSEcCtD
Tafluprost—Nasopharyngitis—Zidovudine—acquired immunodeficiency syndrome	0.0124	0.0142	CcSEcCtD
Tafluprost—Urinary tract infection—Stavudine—acquired immunodeficiency syndrome	0.0119	0.0137	CcSEcCtD
Tafluprost—Eye pain—Ritonavir—acquired immunodeficiency syndrome	0.0119	0.0137	CcSEcCtD
Tafluprost—Rhinitis—Nelfinavir—acquired immunodeficiency syndrome	0.0111	0.0127	CcSEcCtD
Tafluprost—Rhinitis—Stavudine—acquired immunodeficiency syndrome	0.011	0.0127	CcSEcCtD
Tafluprost—Nasopharyngitis—Efavirenz—acquired immunodeficiency syndrome	0.0109	0.0125	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.0107	0.0807	CbGpPWpGaD
Tafluprost—Asthma—Efavirenz—acquired immunodeficiency syndrome	0.0105	0.0121	CcSEcCtD
Tafluprost—Eye disorder—Nelfinavir—acquired immunodeficiency syndrome	0.0103	0.0119	CcSEcCtD
Tafluprost—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00968	0.0112	CcSEcCtD
Tafluprost—Urinary tract infection—Indinavir—acquired immunodeficiency syndrome	0.00962	0.0111	CcSEcCtD
Tafluprost—Rhinitis—Zidovudine—acquired immunodeficiency syndrome	0.00958	0.011	CcSEcCtD
Tafluprost—Asthma—Ritonavir—acquired immunodeficiency syndrome	0.00928	0.0107	CcSEcCtD
Tafluprost—Asthma—Saquinavir—acquired immunodeficiency syndrome	0.00893	0.0103	CcSEcCtD
Tafluprost—Nasopharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00882	0.0102	CcSEcCtD
Tafluprost—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.0087	0.01	CcSEcCtD
Tafluprost—Rhinitis—Efavirenz—acquired immunodeficiency syndrome	0.00842	0.00971	CcSEcCtD
Tafluprost—Cough—Stavudine—acquired immunodeficiency syndrome	0.00835	0.00963	CcSEcCtD
Tafluprost—Cough—Abacavir—acquired immunodeficiency syndrome	0.00823	0.00949	CcSEcCtD
Tafluprost—Rhinitis—Delavirdine—acquired immunodeficiency syndrome	0.00805	0.00929	CcSEcCtD
Tafluprost—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.00804	0.00928	CcSEcCtD
Tafluprost—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00793	0.00915	CcSEcCtD
Tafluprost—Eye disorder—Efavirenz—acquired immunodeficiency syndrome	0.00785	0.00905	CcSEcCtD
Tafluprost—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.00774	0.00893	CcSEcCtD
Tafluprost—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00766	0.00883	CcSEcCtD
Tafluprost—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00755	0.0087	CcSEcCtD
Tafluprost—Rhinitis—Ritonavir—acquired immunodeficiency syndrome	0.00745	0.00859	CcSEcCtD
Tafluprost—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.00729	0.00841	CcSEcCtD
Tafluprost—Cough—Zidovudine—acquired immunodeficiency syndrome	0.00726	0.00837	CcSEcCtD
Tafluprost—Rhinitis—Saquinavir—acquired immunodeficiency syndrome	0.00717	0.00827	CcSEcCtD
Tafluprost—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.00698	0.00805	CcSEcCtD
Tafluprost—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00698	0.00805	CcSEcCtD
Tafluprost—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.00694	0.00801	CcSEcCtD
Tafluprost—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.00689	0.00794	CcSEcCtD
Tafluprost—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00686	0.00791	CcSEcCtD
Tafluprost—Rhinitis—Lamivudine—acquired immunodeficiency syndrome	0.00684	0.00789	CcSEcCtD
Tafluprost—Cough—Indinavir—acquired immunodeficiency syndrome	0.00675	0.00778	CcSEcCtD
Tafluprost—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.00668	0.00771	CcSEcCtD
Tafluprost—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00666	0.00768	CcSEcCtD
Tafluprost—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.00659	0.0076	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00659	0.0496	CbGpPWpGaD
Tafluprost—Cough—Efavirenz—acquired immunodeficiency syndrome	0.00638	0.00735	CcSEcCtD
Tafluprost—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00636	0.00734	CcSEcCtD
Tafluprost—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00619	0.00714	CcSEcCtD
Tafluprost—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00618	0.00713	CcSEcCtD
Tafluprost—Cough—Delavirdine—acquired immunodeficiency syndrome	0.0061	0.00704	CcSEcCtD
Tafluprost—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00609	0.00703	CcSEcCtD
Tafluprost—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00605	0.00698	CcSEcCtD
Tafluprost—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00585	0.00675	CcSEcCtD
Tafluprost—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00572	0.0066	CcSEcCtD
Tafluprost—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00564	0.00651	CcSEcCtD
Tafluprost—Headache—Didanosine—acquired immunodeficiency syndrome	0.00564	0.0065	CcSEcCtD
Tafluprost—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00563	0.00649	CcSEcCtD
Tafluprost—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00554	0.00639	CcSEcCtD
Tafluprost—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00553	0.00637	CcSEcCtD
Tafluprost—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00544	0.00628	CcSEcCtD
Tafluprost—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00543	0.00626	CcSEcCtD
Tafluprost—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00532	0.00613	CcSEcCtD
Tafluprost—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00518	0.00598	CcSEcCtD
Tafluprost—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00518	0.00597	CcSEcCtD
Tafluprost—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00509	0.00587	CcSEcCtD
Tafluprost—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00507	0.00584	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00502	0.0378	CbGpPWpGaD
Tafluprost—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00498	0.00574	CcSEcCtD
Tafluprost—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00491	0.00566	CcSEcCtD
Tafluprost—Headache—Stavudine—acquired immunodeficiency syndrome	0.00489	0.00564	CcSEcCtD
Tafluprost—Headache—Abacavir—acquired immunodeficiency syndrome	0.00482	0.00556	CcSEcCtD
Tafluprost—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.0048	0.00554	CcSEcCtD
Tafluprost—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00475	0.00548	CcSEcCtD
Tafluprost—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00471	0.00543	CcSEcCtD
Tafluprost—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00453	0.00522	CcSEcCtD
Tafluprost—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00447	0.00515	CcSEcCtD
Tafluprost—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00432	0.00498	CcSEcCtD
Tafluprost—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00425	0.0049	CcSEcCtD
Tafluprost—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00422	0.00487	CcSEcCtD
Tafluprost—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00404	0.00466	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00399	0.0301	CbGpPWpGaD
Tafluprost—Headache—Indinavir—acquired immunodeficiency syndrome	0.00396	0.00456	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00386	0.0291	CbGpPWpGaD
Tafluprost—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00374	0.00431	CcSEcCtD
Tafluprost—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00373	0.00431	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00361	0.0272	CbGpPWpGaD
Tafluprost—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00359	0.00414	CcSEcCtD
Tafluprost—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00358	0.00412	CcSEcCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.00348	0.0262	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.00344	0.0259	CbGpPWpGaD
Tafluprost—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00343	0.00395	CcSEcCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.00338	0.0255	CbGpPWpGaD
Tafluprost—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00331	0.00381	CcSEcCtD
Tafluprost—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00318	0.00367	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00304	0.0229	CbGpPWpGaD
Tafluprost—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00304	0.0035	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00275	0.0207	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.0026	0.0196	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00258	0.0194	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00247	0.0186	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00245	0.0184	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—acquired immunodeficiency syndrome	0.00225	0.0169	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00223	0.0168	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—acquired immunodeficiency syndrome	0.00222	0.0167	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—acquired immunodeficiency syndrome	0.00219	0.0165	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0021	0.0158	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0021	0.0158	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.00205	0.0154	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00188	0.0141	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	0.00186	0.014	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.00182	0.0137	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.0017	0.0128	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00168	0.0126	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.0016	0.012	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.0016	0.012	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.0016	0.012	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.00159	0.012	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00156	0.0117	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00152	0.0115	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.0015	0.0113	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00144	0.0108	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00141	0.0106	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.00132	0.00996	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00122	0.00915	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.00118	0.00885	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.0011	0.00829	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00109	0.00824	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.00101	0.0076	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000964	0.00726	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00096	0.00723	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000922	0.00694	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000922	0.00694	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000922	0.00694	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.000915	0.00689	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000903	0.00679	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000903	0.00679	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000872	0.00656	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	0.000856	0.00645	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	0.000844	0.00635	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000842	0.00634	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000834	0.00627	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00082	0.00617	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00082	0.00617	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000687	0.00517	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000676	0.00509	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000666	0.00501	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000659	0.00496	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000624	0.00469	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000619	0.00466	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000614	0.00462	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000592	0.00445	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000569	0.00429	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000562	0.00423	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	0.000545	0.0041	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	0.000529	0.00398	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000515	0.00388	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000505	0.0038	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000484	0.00364	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000484	0.00364	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00045	0.00339	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	0.00044	0.00331	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	0.000431	0.00324	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	0.00043	0.00323	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000368	0.00277	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000363	0.00273	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000357	0.00269	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	0.000348	0.00262	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000332	0.0025	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000325	0.00244	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000293	0.00221	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	0.000226	0.0017	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000207	0.00156	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000192	0.00144	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000191	0.00144	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	0.000155	0.00116	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000113	0.000848	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	9.71e-05	0.000731	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	9.23e-05	0.000695	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	5.25e-05	0.000395	CbGpPWpGaD
